The Korean Journal of Medicine

  • 제87권6호
  • /
  • Pages.647-651
  • /
  • 2014
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

약물 알레르기의 사회적 부담과 관리

Social Burden of Drug Allergy and its Prevention

  • 박중원 (연세대학교 의과대학 내과학교실)
  • Park, Jung-Won (Department of Internal Medicine, Yonsei University College of Medicine)
  • 발행 : 2014.12.01
⟨ 이전 논문 다음 논문 ⟩

초록

Drug allergy exhibits a wide range of clinical features that partly reflect the diversity of the underlying responsible mechanisms. These range from non-immunologic idiosyncratic reactions to Gell and Coombs type 1, 2, 3, and 4 reactions. Consequently, a drug allergy may be difficult to differentiate from an adverse drug reaction. The prevalence of drug allergy varies but is assumed to account for 30% of all adverse drug reactions. In the U.S., 3.1-6.2% of all ward patients are admitted because of adverse drug reactions, and 5-10% of all out-patients or ward patients have suffered an adverse drug reaction. Nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, and radiocontrast media are the most common causes of drug allergy, but with the recent introduction of molecular anti-cancer agents, the number of drug allergy cases by these agents is soaring. Drug allergy is an important cause of mortality in admitted patients, and 1 out of every 10,000 admitted patients will die because of a drug allergy. Approximately 30% of adverse drug reactions can be prevented if previous reactions have been monitored and managed adequately. In 2006, a regional pharmacovigilance program was launched in Korea. In addition, the Korean Institute of Drug Safety and Risk Management plans to develop a nationwide drug utilization review program to monitor adverse drug reactions and to provide relevant information from the program to health professionals working in hospitals and clinics, with the aim of preventing drug allergies. Recent studies have shown a strong association between human leukocyte antigen genotypes and the severe cutaneous adverse reactions (SCARs) induced by certain drugs. Genotype prescreening may contribute to the prevention of SCARs induced by culprit drugs such as carbamazepine, allopurinol, and abacavir.

키워드

참고문헌

  1. Edvards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-1259. https://doi.org/10.1016/S0140-6736(00)02799-9
  2. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 1977;21:247-254. https://doi.org/10.1002/cpt1977213247
  3. Celik G, Pichler WJ, Adkinson NF. Drug allergy. In: Adkinson NF, Bochner BS, Burks AW, et al., eds. Middletone's Allergy: principles and practice. 8th ed. Philadelpia: Elsevier Health Sciences, 2013: 1274-1295.
  4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-1205. https://doi.org/10.1001/jama.279.15.1200
  5. Fattinger K, Roos M, Vergères P, et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000;49:158-167.
  6. Thong BY, Leong KP, Tang CY, Chng HH. Drug allergy in general hospital: results of novel prospective inpatient reporting system. Ann Allergy Asthma Immunol 2003;90:342-347. https://doi.org/10.1016/S1081-1206(10)61804-2
  7. Gomes E, Cardoso MF, Praca F, Gomes L, Marino E, Demoly P. Self-reported drug allergy in a general adult Portuguese population. Clin Exp Allergy 2004;34:1597-1601. https://doi.org/10.1111/j.1365-2222.2004.02070.x
  8. Brockow K, Christiansen C, Kanny G, et al. Management of hypersensitivity reactions to iodinated contrast media. Allergy 2005;60:150-158. https://doi.org/10.1111/j.1398-9995.2005.00745.x
  9. Kemp SF, Lockey RF, Wolf BL, Lieberman P. Anaphylaxis. A review of 266 cases. Arch Intern Med 1995;155:1749-1754. https://doi.org/10.1001/archinte.1995.00430160077008
  10. Helbling A, Hurni T, Mueller UR, Pichler WJ. Incidence of anaphylaxis with circulatory symptoms: a study over a 3-year period comprising 940,000 inhabitants of the Swiss Canton Bern. Clin Exp Allergy 2004;34:285-290. https://doi.org/10.1111/j.1365-2222.2004.01882.x
  11. Brown AF, McKinnon D, Chu K. Emergency department anaphylaxis: a review of 142 patients in a single year. J Allergy Clin Immunol 2001;108:861-866. https://doi.org/10.1067/mai.2001.119028
  12. Moon IJ, Park HJ, Koh BS, et al. Anaphylaxis caused by drugs: in a single tertialry hospital. Korean J Med 2015 Mar [In press].
  13. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. BMJ 2004;329:15-19. https://doi.org/10.1136/bmj.329.7456.15
  14. Mockenhaupt M, Schopf E. Epidemiology of drug-induced severe skin reactions. Semin Cutan Med Surg 1996;15:236-243. https://doi.org/10.1016/S1085-5629(96)80036-8
  15. Strom BL, Carson JL, Halpern AC, et al. A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures. Arch Dermatol 1991;127:831-838. https://doi.org/10.1001/archderm.1991.01680050075007
  16. Harr T, French LE. Toxic epidermal necrolysis and Stevens- Johnson syndrome. Orphanet J Rare Dis 2010;5:39. https://doi.org/10.1186/1750-1172-5-39
  17. Flabbee J, Petit N, Jay N, et al. The economic costs f severe anaphylaxis in France: an inquiry carried out by the Allergy Vigilance Network. Allergy 2008;63:360-365. https://doi.org/10.1111/j.1398-9995.2007.01513.x
  18. Ray S, Bonthapally V, Holen KD, et al. Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors. J Med Econ 2013;16:221-230. https://doi.org/10.3111/13696998.2012.749789
  19. Rosen AC, Case EC, Dusza SW, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol 2013;14:327-333. https://doi.org/10.1007/s40257-013-0021-0
  20. Ra HS, Shin SJ, Kim JH, Lim H, Cho BC, Roh MR. The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients. J Eur Acad Dermatol Venereol 2013;27:e53-59. https://doi.org/10.1111/j.1468-3083.2012.04466.x
  21. Borovicka JH, Calahan C, Gandhi M, et al. Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents. Arch Dermatol 2011;147:1403-1409. https://doi.org/10.1001/archdermatol.2011.719
  22. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE prevention study group. JAMA 1995;274:29-34. https://doi.org/10.1001/jama.1995.03530010043033
  23. Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011;364:1126-1133. https://doi.org/10.1056/NEJMoa1009717
  24. Dong D, Sung C, Finkelstein EA. Cost-effectiveness of HLAB* 1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology 2012;79:1259-1267. https://doi.org/10.1212/WNL.0b013e31826aac73
  25. Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008;9:1543-1546. https://doi.org/10.2217/14622416.9.10.1543
  26. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-579. https://doi.org/10.1056/NEJMoa0706135
  27. Yip VL, Alfirevic A, Pirmohamed M. Genetics of immunemediated adverse drug reactions: a comprehensive and clinical review. Clin Rev Allergy Immunol 2014 Apr 30 [Epub ahead of print].

피인용 문헌

  1. Prevalence and clinical features of hypersensitivity reaction to contrast media after prescreening skin test vol.4, pp.6, 2014, https://doi.org/10.4168/aard.2016.4.6.442
  2. Clinical Features of Serious Adverse Drug Reactions in a Tertiary Care Hospital in Korea vol.92, pp.4, 2014, https://doi.org/10.3904/kjm.2017.92.4.392